322 related articles for article (PubMed ID: 38587757)
1. Nanomedicines via the pulmonary route: a promising strategy to reach the target?
Guérin M; Lepeltier E
Drug Deliv Transl Res; 2024 Aug; 14(8):2276-2297. PubMed ID: 38587757
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicines for intranasal delivery: understanding the nano-bio interactions at the nasal mucus-mucosal barrier.
Hua T; Li S; Han B
Expert Opin Drug Deliv; 2024 Apr; 21(4):553-572. PubMed ID: 38720439
[TBL] [Abstract][Full Text] [Related]
3. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches.
Wang W; Huang Z; Huang Y; Zhang X; Huang J; Cui Y; Yue X; Ma C; Fu F; Wang W; Wu C; Pan X
Adv Drug Deliv Rev; 2022 Jun; 185():114309. PubMed ID: 35469997
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicines and nanodiagnostics come of age.
Uchegbu IF; Siew A
J Pharm Sci; 2013 Feb; 102(2):305-10. PubMed ID: 23175462
[TBL] [Abstract][Full Text] [Related]
7. High drug-loading nanomedicines: progress, current status, and prospects.
Shen S; Wu Y; Liu Y; Wu D
Int J Nanomedicine; 2017; 12():4085-4109. PubMed ID: 28615938
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery.
Rabiei M; Kashanian S; Samavati SS; Derakhshankhah H; Jamasb S; McInnes SJP
J Drug Target; 2022 Mar; 30(3):233-243. PubMed ID: 34415800
[TBL] [Abstract][Full Text] [Related]
9. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in mucus-penetrating nanomedicines for oral treatment of colonic diseases.
Xu C; Xu H; Zhu Z; Shi X; Xiao B
Expert Opin Drug Deliv; 2023; 20(10):1371-1385. PubMed ID: 37498079
[TBL] [Abstract][Full Text] [Related]
11. What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?
Kumar A; Forbes B; Mudway I; Bicer EM; Dailey LA
Nanomedicine (Lond); 2015 Feb; 10(3):343-5. PubMed ID: 25707971
[No Abstract] [Full Text] [Related]
12. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
14. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
Haque S; Whittaker MR; McIntosh MP; Pouton CW; Kaminskas LM
Nanomedicine; 2016 Aug; 12(6):1703-24. PubMed ID: 27033834
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicines for the Treatment of CNS Diseases.
Reynolds JL; Mahato RI
J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Noninvasive Delivery of mRNA.
Qin M; Du G; Sun X
Acc Chem Res; 2021 Dec; 54(23):4262-4271. PubMed ID: 34756014
[TBL] [Abstract][Full Text] [Related]
18. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
19. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
Shahiwala A
Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
[TBL] [Abstract][Full Text] [Related]
20. Breathable Medicine: Pulmonary Mode of Drug Delivery.
Gandhimathi C; Venugopal JR; Sundarrajan S; Sridhar R; Tay SS; Ramakrishna S; Kumar SD
J Nanosci Nanotechnol; 2015 Apr; 15(4):2591-604. PubMed ID: 26353470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
